🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "major milestone" in the battle against drug-resistant strains of the infection, according to health experts.

A Global Challenge

Gonorrhoea infections are escalating globally, with data suggesting in excess of 82 million instances each year. Notably increased rates are observed in Africa and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune step in the reality of increasing worldwide cases, escalating drug resistance and the very limited available drugs presently on offer.”

Medical experts are deeply concerned about the surge in treatment-resistant strains. The World Health Organization has listed it as a "critical concern". A tracking program found that the effectiveness of standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Gain Clearance

One new antibiotic, alternatively called a brand name, was approved by the US FDA in mid-December for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers hope that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, created by the drugmaker GSK, gained clearance in close succession. This medication, which is additionally indicated for UTIs, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The charitable organization GARDP collaborated with the drug firm its industry partner to bring it to fruition.

“This approval represents a major breakthrough in the management of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Clinical Trial Results and Worldwide Availability

According to results detailed in a prominent scientific publication, zoliflodacin cured more than 90% of genital gonorrhoea infections. This establishes an similar efficacy with the typical regimen, which uses a dual-drug approach. The study involved nearly 1,000 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Clinicians on the front lines have expressed positive views. Access to a easy-to-administer therapy such as this is described as a "revolutionary step" for public health efforts. This is viewed as essential to alleviate the strain of the infection for individuals and to halt the transmission of untreatable gonorrhoea worldwide.